CLINICAL_TRIALS
trial_result
· 2023-05-17
Clinical Trial Update: Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer [Phase 2]
Summary
Phase II open-label trial of Tarceva in women with metastatic, hormone- and HER2-negative breast cancer was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Rush University Medical Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-05-17